Slide 1: Myriad Genetics Acquisition of Assurex Health
Myriad Genetics Acquisition of Assurex Health 08/03/2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Strategic Rationale, Consideration and Financial Considerations
Myriad Genetics Acquisition of Assurex Health Strategic Rationale Allows entry into the attractive neuroscience market Synergistic product within strategy Best in class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team
Slide 4: Strategic Rationale
Strategic Rationale Allows entry into attractive neuroscience market Synergistic product within 4in6 strategy Best-in-class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team to sell GeneSight
Slide 5: Neuroscience a Blue Ocean Opportunity in Personalized Medicine
Neuroscience a “Blue Ocean” Opportunity in Personalized Medicine PENETRATION OF PERSONALIZED MEDICINE High Moderate Low “Blue Ocean” Autoimmune Disease Oncology Urology Preventive Care Neuroscience Dermatology Low Moderate High SPENDING Bubble size = healthcare spend
Slide 6: Neuroscience Disorders Affect Almost 1 in 4 Americans
Neuroscience Disorders Affect Almost 1 in 4 Americans Total Spending: >$150B in annual direct healthcare costs ≈6% of total healthcare spending Large amount of waste 76 Million Americans Affected by Mental Disorders
Slide 7: Strategic Rationale
Strategic Rationale Allows entry into attractive neuroscience market Synergistic product within 4in6 strategy Best-in-class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team to sell GeneSight
Slide 8: Strategic Fit – Establishes Last Business Unit
Strategic Fit – Establishes Last Business Unit Currently Marketed Under Development Risk? Diagnosis? Prognosis? Therapy? Oncology Preventive Care Urology Dermatology Neuroscience Autoimmune BIPOLAR
Slide 9: Acquisition Brings Significant Sales Channel to Psychiatrists
Acquisition Brings Significant Sales Channel to Psychiatrists; Completes Build Out CURRENT PRODUCTS FUTURE PRODUCTS myRisk BRCA CDx EndoPredict myChoice HRD myRisk myPath Bipolar GeneSight myPath Endometriosis Vectra DA Psoriatic Arthritis Prolaris myPlan Renal Cancer myPath Prostate myPath Melanoma
Slide 10: Strategic Rationale
Strategic Rationale Allows entry into attractive neuroscience market Synergistic product within 4in6 strategy Best-in-class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team to sell GeneSight
Slide 11: Why do we need GeneSight?
Why do we need ? Historically neuropsychiatric medications were prescribed by trial and error method – leads to “medication odyssey.” A delay in effective treatment can significantly complicate the treatment process, extend symptom severity, reduce patients tolerance and response to subsequent medic
Slide 12: Therapy Response and Treatment Intolerance Increase With Subsequent Therapies
Therapy Response and Treatment Intolerance Increase With Subsequent Therapies DRUG TRIAL
Slide 13: Current Market Opportunity (Patients)
Current Market Opportunity (Patients) 31M patients on antidepressants 2.5M cases of TRD* per year *TRD = Treatment Resistant Depression 58% seen by primary care Current Market Anxiety – 60M Bipolar Disorder – 6M Schizophrenia – 3M Pain – 50M ADHD – 6M Short Term: Long Term: Additional Indications Be
Slide 14: Current Market Opportunity (Dollars)
Current Market Opportunity (Dollars) *Currently approved market Based upon $2,000 average selling price assumption Global Markets mental health (annual prevalence) U.S. 76M Canada 4M Europe 83M Total U.S. Market Opportunity $18.3B Depression All Other Mental Health Psychiatry Non-Psychiatry $2.1B* $
Slide 15: What is GeneSight?
What is ? Data on 55 antidepressants covering 95% of prescriptions for depression, bipolar disorder, anxiety and schizophrenia. Analyzed on MassARRAY platform 331,776 unique GeneSight report genetic combinations and medication recommendations
Slide 16: GeneSight Report Is Easy to Use
. “et xs 4%genesight Report Is Easy to Use
Slide 17: Testing Process for GeneSight
Testing Process for**yenesight ) Simple Buccal Swab to collect DNA © <1 minute Overnight with Pre- = Paid FedEx qm ¢ Genetically Clear and Appropriate Actionable Prescription Results °, S 3 Analyzed at at Assurex CLIA, CAP Accredited Lab © < 36 hours Proprietary Algorithm
Slide 18: Outstanding Data Dossier Which Is Complete For Payer Coverage
Outstanding Data Dossier Which Is Complete For Payer Coverage Analytical Validation Economic Utility Payer Requirements Clinical Utility Clinical Validation
Slide 19: Multiple Genes Play a Well Documented Role in Drug Metabolism
Multiple Genes Play a Well Documented Role in Drug Metabolism and Effectiveness HLA-A*3101 HLA-B*1502 SLC6A4 HTR2A CYP2D6 CYP2C19 CYP2C9 CYP3A4 CYP2B6 CYP1A2 UGT1A4 UGT2B15 Pharmacodynamic Genes Pharmacokinetic Genes >750 published studies supporting impact of genomic alterations in drug response FD
Slide 20: Strong Clinical Utility in Multiple Studies
Strong Clinical Utility in Multiple Studies (n=258) P=0.28 (small study) P=0.04 P<0.0001 *Mean reduction at 8 weeks **Mean reduction at 10 weeks Average 14.9% Reduction in HAM-D17
Slide 21: Strong Clinical Utility Demonstrated in Multiple Studies
Strong Clinical Utility Demonstrated in Multiple Studies (n=258) Mean Improvement in HAM-D17 FDA Approved Medications* “A large between-drug difference could conceivably be 7% in HamD score - Far more likely would be a difference of 5% in HamD score.” Robert Temple, MD, Deputy Center Director for Cl
Slide 22: Substantial Savings to the Healthcare System
Substantial Savings to the Healthcare System p=0.01 p=0.06 p=0.1 p=0.04 p=0.01 p=0.003 4x More Disability Claims 3x More Medical Absence Days 69% More Healthcare Visits Union Health Services (n=96) $1,556 Health Care Savings1,2 Medco Health Solutions (n=13,048) $1,036 Drug Spend Savings3 p=0.0007 Pa
Slide 23: Current Payer Landscape
Current Payer Landscape Payer Mix for GeneSight (Volume) Value Based Pricing Medicare LCD covers treatment resistant depression patients seen by a psychiatrist Horizon BCBS New Jersey is first major private payer to contract for GeneSight 81 million covered lives in aggregate Contracted pricing > $2
Slide 24: Physician Acceptance To Date
Physician Acceptance To Date 48,000 Psychiatrists 7,000 Ordering doctors to date 82% Repeat users 13,600 Psychiatrists (who write 80% of anti-depressant prescriptions) Rx
Slide 25: GeneSight Is One of the Fastest Growing New Diagnostic Tests in History
GeneSight Is One of the Fastest Growing New Diagnostic Tests in History Less than 5% market penetration to date GeneSight (MYGN)
Slide 26: Substantial Barriers to Entry
Biorepository and database on genetic, clinical, and health record outcomes of 300,000 patients and growing First mover advantage Sales channel Trade secrets Extensive clinical development program 55 patents worldwide and 29 pending applications Substantial Barriers to Entry
Slide 27: Strategic Rationale
Strategic Rationale Allows entry into attractive neuroscience market Synergistic product within 4in6 strategy Best-in-class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team to sell GeneSight
Slide 28: Assurex Provides Sales Channel for myPath Bipolar
Assurex Provides Sales Channel for myPath Bipolar Myriad developing differential diagnosis product for major depressive disorder (MDD) and bipolar disorder (BP) 20 million patients per year present with symptoms consistent with MDD or BP Bipolar patients do not respond to first-line or subsequent th
Slide 29: Anticipated Launch of myPath Bipolar in FY19
Anticipated Launch of myPath Bipolar in FY19 Multimarker proteomic assay run on Myriad-RBM Luminex platform Consists of 18 protein analytes from blood Discovery completed in 150 well- characterized BD1 and MDD samples – outstanding early data Prospective validation study currently underway at multip
Slide 30: Additional Prospective Studies Underway For Indication Expansion
Additional Prospective Studies Underway For Indication Expansion Anxiety – 60M patients Today Bipolar Disorder – 5M patients Schizophrenia – 3M patients Pain – 50M patients ADHD – 6M patients
Slide 31: Strategic Rationale
Strategic Rationale Allows entry into attractive neuroscience market Synergistic product within 4in6 strategy Best-in-class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team to sell GeneSight
Slide 32: Most MDD Patients are Seen in Primary Care
Most MDD Patients are Seen in Primary Care Treating Physician for Patients With MDD Significant shortage of psychiatrists in U.S. and getting worse Most MDD patients are seen by primary care consisting of general practice, internal medicine, and OBGYNs Top 16,000 primary care physicians and OBGYN ch
Slide 33: Non-Psychiatrists Follow GeneSight Recommendations More Often and Save More Money
Non-Psychiatrists Follow GeneSight Recommendations More Often and Save More Money Non-Psych Psych Yes No Non-Psych Psych Non-Psychiatrist followed GeneSight more than Psychiatrists Non-Psychiatrist saved 2.5x more than Psychiatrists 33 Total Medication Cost Δ = $3,360 Δ = $1,308 Yes No Yes No Yes No
Slide 34: Submitting LCD to Medicare; Myriad Can Utilize Preventive Care Channel
Submitting LCD to Medicare; Myriad Can Utilize Preventive Care Channel to Sell GeneSight Large GeneSight study published in July of 2015 (n≈13,000) in Current Medical Research and Opinion following current Medicare LCD that was issued in October 2014. The majority of physicians in the study were non
Slide 35: Strategic Rationale, Consideration and Financial Considerations
Myriad Genetics Acquisition of Assurex Health Strategic Rationale Allows entry into the attractive neuroscience market Synergistic product within strategy Best in class product in large market Ability to leverage psychiatry call point with future products Future opportunity for Preventive Care team